|
|
||||||||




* Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; Departments of
Medicine and Microbiology and Immunology and
Pathology, Vanderbilt University School of Medicine, Nashville, TN 37232; and
Department of Medicine (Biostatistics), Harvard University School of Medicine, Boston, MA 02115
Although well studied in settings of helminth infection and allergen sensitization, the combined contributions of IL-4 and IL-13 and their signaling pathways in models of viral pathogenesis have not been reported. Using a murine model of respiratory syncytial virus (RSV) infection, we evaluated the contribution of IL-13, alone and in conjunction with IL-4, during immunization with recombinant vaccinia virus expressing RSV G glycoprotein (vvGs) or with formalin-inactivated RSV (FI-RSV). We showed that both IL-4 and IL-13 activity must be inhibited to modulate G-specific responses resulting in severe RSV-induced disease. Inhibition of IL-4 or IL-13 activity alone had minimal impact on disease in vvGs-immunized mice. However, treatment of IL-4-deficient mice with IL-13Ra during vvGs immunization reduced IL-5, IL-13, and eotaxin production and pulmonary eosinophilia after RSV challenge. In contrast, FI-RSV-induced immune responses were diminished when either IL-4 or IL-13 activity was blocked. After RSV challenge, these type 2 T cell responses were also diminished in vvGs-primed IL-4R
-deficient mice. Our data suggest that secreted vvGs uses mechanisms requiring signaling through the IL-4R
-chain by either IL-4 or IL-13 for induction of eosinophilia and is the first description of the relative contributions of IL-4, IL-13, and their receptors in viral pathogenesis.
This article has been cited by other articles:
![]() |
T. R. Johnson, M. E. Rothenberg, and B. S. Graham Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein J. Leukoc. Biol., September 1, 2008; 84(3): 748 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Castilow, D. K. Meyerholz, and S. M. Varga IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease J. Immunol., February 15, 2008; 180(4): 2376 - 2384. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Olson and S. M. Varga CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-Enhanced Disease J. Immunol., October 15, 2007; 179(8): 5415 - 5424. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Gomperts, L. J. Kim, S. A. Flaherty, and B. P. Hackett IL-13 Regulates Cilia Loss and foxj1 Expression in Human Airway Epithelium Am. J. Respir. Cell Mol. Biol., September 1, 2007; 37(3): 339 - 346. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Phipps, C. E. Lam, S. Mahalingam, M. Newhouse, R. Ramirez, H. F. Rosenberg, P. S. Foster, and K. I. Matthaei Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus Blood, September 1, 2007; 110(5): 1578 - 1586. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Monick, L. S. Powers, I. Hassan, D. Groskreutz, T. O. Yarovinsky, C. W. Barrett, E. M. Castilow, D. Tifrea, S. M. Varga, and G. W. Hunninghake Respiratory Syncytial Virus Synergizes with Th2 Cytokines to Induce Optimal Levels of TARC/CCL17 J. Immunol., August 1, 2007; 179(3): 1648 - 1658. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Melendi, F. R. Laham, A. C. Monsalvo, J. M. Casellas, V. Israele, N. R. Polack, S. R. Kleeberger, and F. P. Polack Cytokine Profiles in the Respiratory Tract During Primary Infection With Human Metapneumovirus, Respiratory Syncytial Virus, or Influenza Virus in Infants Pediatrics, August 1, 2007; 120(2): e410 - e415. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Martinez, L. Lombardia, B. Garcia-Barreno, O. Dominguez, and J. A. Melero Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells J. Gen. Virol., February 1, 2007; 88(2): 570 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bukreyev, M. E. Serra, F. R. Laham, G. A. Melendi, S. R. Kleeberger, P. L. Collins, and F. P. Polack The Cysteine-Rich Region and Secreted Form of the Attachment G Glycoprotein of Respiratory Syncytial Virus Enhance the Cytotoxic T-Lymphocyte Response despite Lacking Major Histocompatibility Complex Class I-Restricted Epitopes. J. Virol., June 1, 2006; 80(12): 5854 - 5861. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Peebles Jr. and B. S. Graham Pathogenesis of Respiratory Syncytial Virus Infection in the Murine Model Proceedings of the ATS, August 1, 2005; 2(2): 110 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. Polack, P. M. Irusta, S. J. Hoffman, M. P. Schiatti, G. A. Melendi, M. F. Delgado, F. R. Laham, B. Thumar, R. M. Hendry, J. A. Melero, et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin PNAS, June 21, 2005; 102(25): 8996 - 9001. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Huang and R. Anderson Modulation of Protective Immunity, Eosinophilia, and Cytokine Responses by Selective Mutagenesis of a Recombinant G Protein Vaccine against Respiratory Syncytial Virus J. Virol., April 1, 2005; 79(7): 4527 - 4532. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Z. Wang, Y.-X. Bao, C. L. Rosenberger, Y. Tesfaigzi, J. M. Stark, and K. S. Harrod IL-12p40 and IL-18 Modulate Inflammatory and Immune Responses to Respiratory Syncytial Virus Infection J. Immunol., September 15, 2004; 173(6): 4040 - 4049. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Elliott, K. S. Pryharski, Q. Yu, L. A. Boutilier, N. Campeol, K. Melville, T. S. Laughlin, C. K. Gupta, R. A. Lerch, V. B. Randolph, et al. Characterization of Recombinant Respiratory Syncytial Viruses with the Region Responsible for Type 2 T-Cell Responses and Pulmonary Eosinophilia Deleted from the Attachment (G) Protein J. Virol., August 15, 2004; 78(16): 8446 - 8454. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Johnson, S. M. Varga, T. J. Braciale, and B. S. Graham V{beta}14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV J. Virol., August 15, 2004; 78(16): 8753 - 8760. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Johnson, M. N. Teng, P. L. Collins, and B. S. Graham Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV J. Virol., June 1, 2004; 78(11): 6024 - 6032. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. G. Antonis, R. S. Schrijver, F. Daus, P. J. G. M. Steverink, N. Stockhofe, E. J. Hensen, J. P. M. Langedijk, and R. G. van der Most Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis J. Virol., November 15, 2003; 77(22): 12067 - 12073. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |